List view / Grid view
Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…
3 June 2015 | By Victoria White
MSD has extended its existing collaborative research agreement with Agenus for the discovery and development of therapeutic antibodies...
22 May 2015 | By Victoria White
Eureka Therapeutics and Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology...
6 May 2015 | By Victoria White
The final report on toxicology testing of HuMab 5B1 shows that it had no significant adverse findings even at the highest dosage levels tested...
23 April 2015 | By Victoria White
MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown)...
17 April 2015 | By Victoria White
AnaptysBio has announced the advancement of its first-in-class anti-interleukin-36 receptor (IL-36R) antibody, ANB019, into IND-enabling studies.
9 April 2015 | By J.R.Costa, J.Heintze, R.Ketteler, S. Gul, Dr. T.Duensing, K.Papenfuss.
In this Drug Targets In-Depth Focus, we delve into the role of a key complex required for autophagosome maturation, the ATG4-ATG8 conjugation system, and we provide insight on some up-and-coming immune checkpoint inhibitors that are currently in clinical and preclinical development...
8 April 2015 | By Victoria White
Inovio has been selected to receive a grant from DARPA to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola...
30 March 2015 | By Victoria White
CRT and BioInvent have announced the start of a two-year research collaboration with leading antibody researchers at the University of Southampton...
30 March 2015 | By Victoria White
The MRC and UCB are to launch a collaboration that will provide scientists with access to cutting-edge technologies to discover new monoclonal antibodies...
20 March 2015 | By Victoria White
Probiodrug has announced that the company will present data on its specific pGlu-Abeta mouse antibody 17/1 at AD/PDTM 2015 in Nice, France...
20 March 2015 | By Victoria White
Prothena has announced positive results from a study of PRX002, a monoclonal antibody for the potential treatment of Parkinson's disease...
11 March 2015 | By MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma...
16 December 2014 | By Kymab
Kymab, a monoclonal antibody biopharmaceutical company, founded on research from the Wellcome Trust Sanger Institute announces that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola...
The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…
